Chiesi Farmaceutici has been granted a patent for a modified release tablet containing deferiprone, designed for twice-daily oral administration. The formulation includes specific polymers for delayed release and an enteric coating, ensuring controlled release of the active ingredient under varying pH conditions. GlobalData’s report on Chiesi Farmaceutici gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Chiesi Farmaceutici, Inhalation devices was a key innovation area identified from patents. Chiesi Farmaceutici's grant share as of July 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
Modified release tablets containing deferiprone for oral administration
The granted patent US12016851B2 describes a delayed release tablet formulation primarily composed of deferiprone, a chelating agent used to treat iron overload conditions. The tablet contains approximately 1000 mg of deferiprone, constituting 85.0% to 95.0% of its weight, along with a modifying release agent that includes hydroxypropylmethylcellulose polymers of varying viscosities (100 cP and optionally 4000 cP). The formulation also incorporates a lubricant and/or glidant, additional pharmaceutically acceptable excipients, and an enteric coating. The tablet is designed for oral administration twice daily, demonstrating a controlled release profile where less than 20% of deferiprone is released within 120 minutes at a pH of 1.2, and at least 60% is released within 180 minutes at a pH of 6.8.
The patent further outlines specific components and processes for the tablet's preparation, including the use of various lubricants and glidants, such as magnesium stearate and colloidal silicon dioxide. The enteric coating may consist of specific copolymers and diluents to ensure the tablet's stability and efficacy. Additionally, the patent claims methods for treating diseases associated with iron overload, such as thalassemia and sickle cell anemia, by administering the described delayed release tablet. The detailed formulation and preparation processes aim to enhance the therapeutic effectiveness of deferiprone while minimizing side effects associated with rapid release.
To know more about GlobalData’s detailed insights on Chiesi Farmaceutici, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
